Clinical Trials in London, United Kingdom

2,525 recruiting

Showing 120 of 1,844 trials

Recruiting
Phase 3

A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

Alzheimer DiseaseAgitation
Bristol-Myers Squibb600 enrolled255 locationsNCT06937229
Recruiting
Phase 3

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

Gastroesophageal Junction AdenocarcinomaHER2-positive Gastric Cancer
AstraZeneca840 enrolled293 locationsNCT06764875
Recruiting
Phase 1

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

Diffuse Large B-Cell Lymphoma (DLBCL)Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)+6 more
Nurix Therapeutics, Inc.572 enrolled62 locationsNCT05131022
Recruiting
Phase 2

Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer

Advanced Breast Cancer
AstraZeneca24 enrolled6 locationsNCT07427394
Recruiting
Phase 1Phase 2

Study for AZD4360 in Participants With Advanced Solid Tumours

Gastric CancerGastroesophageal-junction CancerBiliary Tract Cancer+1 more
AstraZeneca117 enrolled18 locationsNCT06921928
Recruiting

Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting

Pulmonary Disease, Chronic Obstructive
AstraZeneca2,000 enrolled7 locationsNCT06712563
Recruiting
Phase 3

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

Plaque Psoriasis
Bristol-Myers Squibb3,040 enrolled383 locationsNCT07116967
Recruiting
Phase 1Phase 2

A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease

Healthy VolunteersAnemia, Sickle Cell
Bristol-Myers Squibb184 enrolled34 locationsNCT06481306
Recruiting
Phase 2

Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Alexion Pharmaceuticals, Inc.75 enrolled78 locationsNCT07160608
Recruiting
Phase 3

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)

Psychosis Associated With Alzheimer's Disease
Karuna Therapeutics, Inc., a Bristol Myers Squibb company500 enrolled154 locationsNCT06126224
Recruiting
Phase 2

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)
Nurix Therapeutics, Inc.100 enrolled30 locationsNCT07221500
Recruiting
Phase 3

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Non-small Cell Lung Cancer
AstraZeneca675 enrolled283 locationsNCT06357533
Recruiting
Phase 1

A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors

Endometrial CancerTesticular CancerPlatinum Resistant Ovarian Cancer
Context Therapeutics Inc.156 enrolled14 locationsNCT06515613
Recruiting
Phase 3

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Multiple Myeloma
Pfizer492 enrolled273 locationsNCT06152575
Recruiting
Phase 1

Study of STP938 (Dencatistat) in Advanced Solid Tumours

Solid Tumor
Step Pharma, SAS70 enrolled7 locationsNCT06297525
Recruiting
Phase 1Phase 2

A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas

Lymphoma, T-CellLymphoma, B-Cell
Step Pharma, SAS180 enrolled15 locationsNCT05463263
Recruiting
Phase 3

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

Breast Neoplasms
Merck Sharp & Dohme LLC1,000 enrolled183 locationsNCT07060807
Recruiting
Phase 3

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma
AbbVie380 enrolled166 locationsNCT06158841
Recruiting
Phase 2

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

Lymphoma, Large B-Cell, Diffuse
Merck Sharp & Dohme LLC594 enrolled127 locationsNCT06890884
Recruiting
Phase 3

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

Non-small Cell Lung Cancer
Boehringer Ingelheim400 enrolled200 locationsNCT07195695